Diabetic Patients
Conditions
Brief summary
The purpose of this study is to evaluate the efficacy and safety of treatment with TAK-875 in diabetic patients.
Interventions
Sponsors
Takeda
Study design
Primary purpose
TREATMENT
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Inclusion criteria
* The participant is an outpatient. * The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
Exclusion criteria
* The participant has any serious cardiac disease, serious cerebrovascular disorder, or any serious pancreatic or hematological disease. * The participant is considered ineligible for the study for any other reason by the investigator or subinvestigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Blood glucose | 4 weeks | Blood glucose |
Countries
Japan
Outcome results
None listed